Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

APOBEC3G: a double agent in defense.

Smith HC.

Trends Biochem Sci. 2011 May;36(5):239-44. doi: 10.1016/j.tibs.2010.12.003. Epub 2011 Jan 14.

2.

[Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].

Fan B, Cen S, Jiang JD.

Yao Xue Xue Bao. 2008 Jul;43(7):678-82. Review. Chinese.

PMID:
18819469
3.

Vif and Apobec3G in the innate immune response to HIV: a tale of two proteins.

Farrow MA, Sheehy AM.

Future Microbiol. 2008 Apr;3(2):145-54. doi: 10.2217/17460913.3.2.145. Review.

PMID:
18366335
4.

Apobec3G-Based Strategies to Defeat HIV Infection.

Ran X, Ao Z, Yao X.

Curr HIV Res. 2016;14(3):217-24. Review.

PMID:
26957196
5.

Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.

Henriet S, Mercenne G, Bernacchi S, Paillart JC, Marquet R.

Microbiol Mol Biol Rev. 2009 Jun;73(2):211-32. doi: 10.1128/MMBR.00040-08. Review.

6.

APOBEC3G: an intracellular centurion.

Chiu YL, Greene WC.

Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):689-703. doi: 10.1098/rstb.2008.0193. Review.

7.

Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.

Smith JL, Bu W, Burdick RC, Pathak VK.

Trends Pharmacol Sci. 2009 Dec;30(12):638-46. doi: 10.1016/j.tips.2009.09.006. Review.

8.

Lentiviral Vif: viral hijacker of the ubiquitin-proteasome system.

Ehrlich ES, Yu XF.

Int J Hematol. 2006 Apr;83(3):208-12. Review.

PMID:
16720549
9.

APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.

Franca R, Spadari S, Maga G.

Med Sci Monit. 2006 May;12(5):RA92-8. Review.

PMID:
16641889
10.

[Recent advances in the study of mechanism of APOBEC3G against virus].

Zhu YP, Jiang JD, Peng ZG.

Yao Xue Xue Bao. 2014 Jan;49(1):30-6. Review. Chinese.

PMID:
24783502
11.

[Progress in the study of HIV-1 Vif and related inhibitors].

Li ZY, Zhan P, Liu XY.

Yao Xue Xue Bao. 2010 Jun;45(6):684-93. Review. Chinese.

PMID:
20939174
12.

Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein.

Münk C, Jensen BE, Zielonka J, Häussinger D, Kamp C.

Viruses. 2012 Nov 14;4(11):3132-61. doi: 10.3390/v4113132. Review.

13.

HIV accessory proteins versus host restriction factors.

Strebel K.

Curr Opin Virol. 2013 Dec;3(6):692-9. doi: 10.1016/j.coviro.2013.08.004. Epub 2013 Nov 15. Review.

14.

Plunder and stowaways: incorporation of cellular proteins by enveloped viruses.

Cantin R, Méthot S, Tremblay MJ.

J Virol. 2005 Jun;79(11):6577-87. Review. No abstract available.

15.

The Road Less Traveled: HIV's Use of Alternative Routes through Cellular Pathways.

Marx A, Alian A.

J Virol. 2015 May;89(10):5204-12. doi: 10.1128/JVI.03684-14. Epub 2015 Mar 11. Review.

16.

Human cellular restriction factors that target HIV-1 replication.

Strebel K, Luban J, Jeang KT.

BMC Med. 2009 Sep 16;7:48. doi: 10.1186/1741-7015-7-48. Review.

17.

HIV Restriction Factors and Mechanisms of Evasion.

Malim MH, Bieniasz PD.

Cold Spring Harb Perspect Med. 2012 May;2(5):a006940. doi: 10.1101/cshperspect.a006940. Review.

18.

Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment.

Monajemi M, Woodworth CF, Benkaroun J, Grant M, Larijani M.

Retrovirology. 2012 Apr 30;9:35. doi: 10.1186/1742-4690-9-35. Review.

19.

Anti-HIV Factors: Targeting Each Step of HIV's Replication Cycle.

Colomer-Lluch M, Gollahon LS, Serra-Moreno R.

Curr HIV Res. 2016;14(3):175-82. Review.

PMID:
26957194
20.

The emerging role of long non-coding RNAs in HIV infection.

Lazar DC, Morris KV, Saayman SM.

Virus Res. 2016 Jan 2;212:114-26. doi: 10.1016/j.virusres.2015.07.023. Epub 2015 Jul 26. Review.

Supplemental Content

Support Center